OBJECTIVE: To report a case of rhabdomyolysis and acute hepatitis associated with the
coadministration of atorvastatin and diltiazem. CASE SUMMARY: A 60-year-old African …

Rhabdomyolysis is a life-threatening clinical and biochemical syndrome that results from
injury to skeletal muscle. Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) …

Background: Simvastatin, a 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitor, is
indicated for the treatment of hypercholesterolemia and plays an important role in both the …

Context Elevated total cholesterol (total‐C) and low‐density lipoprotein cholesterol (LDL‐C)
levels are established risk factors for cardiovascular disease (CVD). HMG‐CoA reductase …

Background Statins have a well-established role in prevention of vascular events but are
associated with muscle-related adverse events. The dose relationship with these adverse …

Background Rhabdomyolysis is a rare but serious complication of lipid-lowering therapy.
Statin and fibrate combination increases the risk of rhabdomyolysis possibly by …

Rhabdomyolysis is a well-documented side effect of statin therapy. This risk is increased
with concurrent use of medications that inhibit cytochrome p450-3A4 (CYP3A4), such as …

Rhabdomyolysis is a rare but life-threatening complication of statin therapy. A 74-year-old
man, treated with atorvastatin, developed rhabdomyolysis after the co-administration of …

Simvastatin is a hydroxymethyl glutaryl coenzyme A reductase inhibitor commonly used to
treat patients with hyperlipidemia. It is a safe and effective medication in most patients when …

aBsTRaCT The placebo-corrected incidence of rhabdomyolysis in a systematic review of 20
statin trials was 1.6/100,000 per year. It is likely to be higher than this in everyday clinical …